Teva Pharmaceutical Industries announced that it has launched sales of irbesartan and irbesartan-hydrochlorothiazide tablets, two generic versions of Sanofi Aventis’ high blood pressure treatments. According to the company, the brand products had annual sales of approximately $464 million and $124 million in the United States, based on sales data from the IMS research firm. In addition, Teva has been awarded a 180-day period of marketing exclusivity.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Agtech Firm Expands In Australia With Local Purchase
December 11, 2023

Israeli Drone Safety Firm In New Partnership To Boost UAV Safety
December 10, 2023

Weizmann Program Boosts Israeli-Canadian Brain Research
December 10, 2023

Israel And UAE Ink New Deal To Connect Ports Via Land Bridge
December 07, 2023
Facebook comments